Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer

Phase 2 Completed 39 enrolled University of Pittsburgh Bristol-Myers Squibb · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if the addition of a unique targeted agent called Cetuximab (also known as "C225" and "Erbitux") can increase the effectiveness of standard treatment with chemotherapy and radiation.

Timeline

Start: 2005-10
Primary completion: 2013-07
Completion: 2013-07

Publications

Psyrri A, Rampias T, Vermorken JB. The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck. Ann Oncol. 2014 Nov;25(11):2101-2115. doi: 10.1093/annonc/mdu265. Epub 2014 Jul 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cetuximab	Monoclonal antibody	250 mg/m2	Intravenous
Background	Cisplatin	Other / unclassified	75 mg/m2	Intravenous
Background	Docetaxel	Small molecule	75 mg/m2	Intravenous

Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer

Summary

Timeline

Publications

Drugs

Indications